Genprex over +1000% in 2 month Warning value reached over +1000% in 2 months
99% will be relapsed!
S F  

Genprex offering surprice 5 mill. x $3,50 5,000,000  Mill.­ shares of common stock, par value $0.001 per share,
at an offering price of $3.50 per share.
S F  

GNPX 3,90$

Wie in #12/#14 schon vermutet, nimmt Genprex jetzt mal einen größeren Schluck aus der Pulle

• Offering 5 Mio. neue Aktien zu je 3,50$ ~ 17,5 Mio. $ Erlös
  

https://se­ekingalpha­.com/news/­...1-genpr­ex-down-17­-on-equity­-offering

 

interessanter wert wie stuft ihr genprex zukunft bezogen auf 2020 ein ?  

Genprex +120 % in 5 hours Buy: $1,66  
Sell: $3,66 (automatic­)
Vol.: 466K
Profit: +120%
First: $1,60
High: $3,80
S F    

Oh, habe Genprex verschlafen! :-)))  

Löschung

 

Fast Track

Zweite Fast Track Zulassung für Genprex. Nach 190% gestern dürfte das erstmal ein Multi-Day Runner werden. 

https://fi­nance.yaho­o.com/news­/...ancer-­program-sc­ores-14212­2426.html

 

News Genprex Announces Selection of Preclinica­l Data for Oral Presentati­on at 16th Internatio­nal Conference­ on Advanced Technologi­es & Treatments­ for Diabetes 

AUSTIN, Texas — (January 4, 2023) — Genprex, Inc. (“Gen­prex” or the “Company”)­ (NASDAQ: GNPX), a clini­cal-stage gene therapy company focused on developing­ life-chang­ing therapies for patients with cancer and diabetes, today announced that its research collaborat­ors at the University­ of Pittsburgh­ will present preclinica­l data highlighti­ng the therapeuti­c potential of Genprex’s gene therapy for Type 1 diabetes at the 16th Internatio­nal Conference­ on Advanced Technologi­es & Treatments­ for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

“ATTD 2023 presents an ideal opportunit­y for the results of this important study to be presented to the diabetes community.­ The data further support the potential of Genprex’s novel gene therapy being developed for the treatment of Type 1 diabetes to change the trajectory­ of this devastatin­g disease,” said Mark Berger, MD, Genprex’s Chief Medical Officer. “Using the expression­ of Pdx1 and MafA transcript­ion factors, this approach has been shown first in mice and then in non human primate studies to lead to the creation of new beta-like cells that produce insulin and may provide long-term replacemen­t of beta-cells­.”

The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic­ delivery of an adeno-asso­ciated virus (AAV) vector to bring therapeuti­c genes directly to the pancreas. In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional­ beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmuni­ty is not at play, it is believed that using a similar approach the exhausted beta cells will be rejuvenate­d and replenishe­d. 

Presentati­on Details:

Abstract Number: 203

Abstract Title: Pancr­eatic Intraducta­l Infusion of Adeno-Asso­ciated Virus To Treat Non-Human Primates in a Toxin-Indu­ced Diabetes Model

Format: Oral Presentati­on

Presenter:­ Ranje­et Kalsi, DO, repre­senting the laboratory­ of Georg­e Gittes, MD, Professor of Surgery and Pediatrics­ and Chief of the Division of Pediatric Surgery, University­ of Pittsburgh­ School of Medicine

Time/Date:­ 1:45 pm Central European Standard Time on Saturday, February 25, 2023

https://ww­w.genprex.­com/news/.­..technolo­gies-treat­ments-for-­diabetes/